Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis.

Authors:
Mauer J; Bullok K; Watt S; Whalen E; Russo L and 4 more

Journal:
Br J Clin Pharmacol

Publication Year: 2022

DOI:
10.1111/bcp.15309

PMCID:
PMC9543715

PMID:
35277997

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Clin Pharmacol

Abbreviation: Br J Clin Pharmacol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel reti…
Goncalves MB; Mant T; Täubel J and 8 more (2023) - Transparency Score: 4/6
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastati…
Lehtisalo M; Taskinen S; Tarkiainen EK and 8 more (2022) - Transparency Score: 3/6
A crossover study evaluating the sex-dependent and sensitizing effects of sleep deprivation using a…
Hijma H; Koopmans I; Klaassen E and 3 more (2022) - Transparency Score: 4/6
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in pat…
Baakman AC; Gavan C; van Doeselaar L and 12 more (2022) - Transparency Score: 4/6
An e-Delphi study to obtain expert consensus on the level of risk associated with preventable e-pre…
Heed J; Klein S; Slee A and 3 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"Funding information Eli Lilly and Company, Grant/Award Number: No grants or awards were provided; Pfizer"

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025